SX-682

• CAT Number: I008854
• CAS Number: 1648843-04-2
• Molecular Formula: C19H14BF4N3O4S
• Molecular Weight: 467.202
• Purity: ≥95%
• Target: Cxcr1/2 inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
• InChI: InChI=1S/C19H14BF4N3O4S/c21-13-1-3-14(4-2-13)27-17(28)12-8-25-18(26-9-12)32-10-11-7-15(31-19(22,23)24)5-6-16(11)20(29)30/h1-9,29-30H,10H2,(H,27,28)
• InChIKey: SDUDZBCEHIZMFZ-UHFFFAOYSA-N
• SMILES: B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O

SX-682 (CAT: I008854) is a small molecule inhibitor that targets the CXCR1 and CXCR2 chemokine receptors. It functions by blocking the interaction between chemokines and their receptors, thereby inhibiting the migration and infiltration of immune cells. SX-682 has shown potential in preclinical studies as an anti-inflammatory and anti-tumor agent by reducing the recruitment of neutrophils and other immune cells to inflammatory or tumor sites. This compound is being investigated for its therapeutic potential in various inflammatory diseases and cancers.

Overview of Clinical Research

SX-682 is an Interleukin 8A/B receptor antagonist. Phase-I clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, First-line therapy) in USA (PO, Pill) (NCT04477343) are ongoing.

Reference

1:Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 20. doi: 10.1038/nature21676. [Epub ahead of print] PubMed PMID: 28321130.